Onyx Pharmaceuticals completes enrollment in FOCUS Phase 3 Carfilzomib trial


Onyx Pharmaceuticals announced that the company completed enrollment in the FOCUS trial, an international Phase 3 clinical trial evaluating single-agent carfilzomib in patients with relapsed and refractory myeloma who have received three or more prior therapies. The FOCUS, or CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study, trial is designed to support regulatory approvals around the world.

View Comments (0)